Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Depreciation & Amortization (CF) (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Depreciation & Amortization (CF) for 10 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 7.88% to $8.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.0 million, a 2.78% decrease, with the full-year FY2025 number at $35.0 million, down 2.78% from a year prior.
  • Depreciation & Amortization (CF) was $8.8 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $8.6 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $9.5 million in Q4 2024 to a low of $3.1 million in Q2 2021.
  • A 5-year average of $6.4 million and a median of $6.3 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 68.93% in 2024, then decreased 7.88% in 2025.
  • Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) stood at $3.5 million in 2021, then skyrocketed by 40.27% to $5.0 million in 2022, then surged by 65.66% to $8.2 million in 2023, then rose by 16.12% to $9.5 million in 2024, then decreased by 7.88% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Depreciation & Amortization (CF) are $8.8 million (Q4 2025), $8.6 million (Q3 2025), and $8.6 million (Q2 2025).